TCW Group Inc. lowered its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 708,121 shares of the biopharmaceutical company’s stock after selling 21,146 shares during the quarter. TCW Group Inc. owned 0.32% of Alexion Pharmaceuticals worth $99,342,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALXN. Jennison Associates LLC increased its position in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. BlackRock Inc. increased its position in shares of Alexion Pharmaceuticals by 7.0% during the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after purchasing an additional 1,298,185 shares during the last quarter. Third Point LLC bought a new position in shares of Alexion Pharmaceuticals during the 2nd quarter valued at approximately $152,088,000. Janus Henderson Group PLC increased its position in shares of Alexion Pharmaceuticals by 1,697.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock valued at $139,424,000 after purchasing an additional 1,082,171 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Alexion Pharmaceuticals by 42.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after purchasing an additional 955,578 shares during the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $1.72 during midday trading on Tuesday, hitting $113.45. The company had a trading volume of 1,620,000 shares, compared to its average volume of 2,289,474. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The stock has a market cap of $25,350.00, a PE ratio of 23.55, a P/E/G ratio of 1.25 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.23 EPS. analysts predict that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current year.

Several equities analysts have recently weighed in on ALXN shares. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price on the stock in a research report on Tuesday, October 31st. Oppenheimer Holdings, Inc. raised Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 target price on the stock in a research report on Friday, July 28th. Royal Bank Of Canada started coverage on Alexion Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $161.00 target price on the stock. Morgan Stanley reissued an “overweight” rating and set a $153.00 target price (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Finally, BidaskClub raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $154.01.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/11/14/tcw-group-inc-has-99-34-million-stake-in-alexion-pharmaceuticals-inc-alxn.html.

In related news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Insiders have sold a total of 16,490 shares of company stock valued at $2,337,251 over the last 90 days. 4.35% of the stock is currently owned by company insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.